Active Runners: Amicus Therapeutics, Inc. (NASDAQ:FOLD), NXP Semiconductors NV (NASDAQ:NXPI)

On Wednesday, Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD), included 2.78% and shut at $9.23 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $8.67 and $9.30. The business’ commercial center capitalization is $1.31 Billion with the aggregate fabulous loads of 142.33 million. Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has accomplished Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson’s disease.

Shares of NXP Semiconductors NV (NASDAQ:NXPI), added 0.50% and shut at $99.33 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $98.50 and $99.52. The association’s commercial center capitalization is $34.46 Billion with the general uncommon loads of 333.46 million. Qualcomm Incorporated (QCOM) recently declared that Qualcomm River Holdings B.V., an indirect wholly owned partner of Qualcomm, has begind the formerly declared tender offer for all of the outstanding common shares of NXP Semiconductors N.V. (NXPI) at a price of $110.00 per share, less any applicable withholding taxes and without interest, to the holders thereof and payable in cash. The tender offer is being made following the Purchase Agreement, dated as of October 27, 2016, by and between Qualcomm River Holdings B.V. and NXP.

A tender offer statement on Plan TO that includes the Offer to Purchase and related Letter of Transmittal that set forth the complete terms and conditions of the tender offer will be filed recently with the U.S. Securities and Exchange Commission by Qualcomm River Holdings B.V. In Addition To, NXP will file with the SEC a solicitation/recommendation statement on Plan 14D-9 recently that includes the recommendation of NXP’s board of directors that NXP shareholders tender their shares in the tender offer.

Leave a Reply

Your email address will not be published. Required fields are marked *